Tacrolimus Market Report, Global, 2024

The tacrolimus market size has grown strongly in recent years. It will grow from $6.2 billion in 2023 to $6.59 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth observed during the historic period can be attributed to several factors, including advancements in transplantation medicine, increased organ transplant procedures, regulatory approvals, expanded applications in dermatology, the prevalence of autoimmune diseases, increased research investments, and enhanced drug delivery technologies.

The tacrolimus market size is expected to see strong growth in the next few years. It will grow to $8.47 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be attributed to several factors, including expanded therapeutic applications, regulatory approvals for new indications, increased investment in research and development, growing awareness and acceptance of immunosuppressant therapies, expanding healthcare infrastructure in emerging markets, and evolving treatment guidelines and protocols. Major trends expected in the forecast period include increased adoption of personalized medicine approaches, advancements in drug delivery systems, expanding applications in autoimmune disorders, rising demand in emerging markets, growing emphasis on bioequivalence studies, development of novel formulations, and integration of pharmacogenomics for optimized dosing regimens.

The upward trend in organ transplant procedures is poised to fuel the expansion of the tacrolimus market in the coming years. Organ transplantation involves surgically replacing a dysfunctional organ with a healthy one from a donor, a procedure vital for improving patient outcomes and quality of life. Factors such as advancements in medical technology, refined surgical techniques, increased awareness about organ donation, and improved post-transplant care contribute to the growing rates of organ transplantation. Tacrolimus plays a crucial role in organ transplantation by inhibiting T-cell activation and reducing cytokine production, thus preventing rejection of the transplanted organ by the recipient's immune system. For instance, in January 2024, the US Department of Health and Human Services reported a total of 46,632 organ transplant procedures from both deceased and living donors, marking an 8.7% increase from 2022 and a 12.7% increase from 2021. Consequently, the surge in organ transplant procedures is a key driver of the tacrolimus market.

Leading companies in the tacrolimus market are focusing on the development of advanced formulations, such as tacrolimus ointments, to cater to the rising demand for innovative treatments for dermatological conditions while also improving patient care. Tacrolimus ointment, containing the immunosuppressive agent tacrolimus, is primarily used to treat inflammatory skin conditions. For example, in August 2023, Glenmark, a pharmaceutical company based in India, received approval from the United States Food and Drug Administration (US FDA) for Tacrolimus Ointment 0.03%, a generic version of Protopic Ointment 0.03%. This medication is prescribed to manage moderate-to-severe atopic dermatitis, a skin condition characterized by inflammation, redness, and itching.

In January 2022, Aequus Pharmaceuticals Inc., a Canadian pharmaceutical company developing Tacrolimus Immediate Release, forged a partnership with Sandoz Inc. This collaboration aims to drive market growth and enhance the presence of tacrolimus, ensuring continued access to a cost-effective and high-quality solution for transplant-related needs across Canada. Sandoz Inc., headquartered in Switzerland, specializes in the production of generic medicines.

Major companies operating in the tacrolimus market are Sinopharm Chuankang Pharmaceutical, F. Hoffmann-La Roche AG, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc, Sandoz Inc, Huadong Medicine Co Ltd, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., LEO Pharma A/S, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Wockhardt Limited, Biocon Ltd., Zydus Lifesciences Limited, Panacea Biotec, RPG Life Science, Sun Pharmaceutical Industries Limited, Tecoland Corporation.

North America was the largest region in the tacrolimus market in 2023 and 2024. The regions covered in the tacrolimus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tacrolimus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tacrolimus is an immunosuppressive medication employed to forestall organ rejection following transplantation. It operates by reducing immune system activity, thus preventing the transplanted organ from being attacked.

The main product types of tacrolimus encompass tacrolimus capsules and tablets, tacrolimus ointment, tacrolimus injection, and tacrolimus granules. Tacrolimus capsules and tablets are pharmaceutical formulations containing tacrolimus, utilized to thwart organ rejection post-transplantation. They serve various purposes including immunosuppression and dermatitis management, and are utilized by diverse end users such as organ transplant centers, hospitals, clinics, and others.

The tacrolimus market research report is one of a series of new reports that provides tacrolimus market statistics, including tacrolimus industry global market size, regional shares, competitors with a tacrolimus market share, detailed tacrolimus market segments, market trends, and opportunities, and any further data you may need to thrive in the tacrolimus industry. This tacrolimus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tacrolimus market consists of sales of oral suspension, extended-release capsules, and extended-release tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.